A Divided Analyst View: Atai Beckley’s $3.8 Billion Lilly Takeover Carries a Milestone Twist
Published on 07/22/2026 at 06:33 | Redaktion boerse-global.de
Eli Lilly’s acquisition of Atai Beckley, valued at up to $3.8 billion, has thrown the psychedelics sector into the spotlight — but the deal’s structure is creating a rare split on Wall Street. While most analysts have rushed to align their price targets with the buyout terms, at least one firm is betting the transaction may not be the final word on the stock’s value.
The agreement, struck on July 16, 2026, sees Lilly pay $6.75 per share in cash upfront, representing roughly $2.8 billion. On top of that, shareholders receive contingent value rights (CVRs) worth up to an additional $2.50 per share, tied to specific clinical and regulatory milestones. If all conditions are met, the total consideration reaches $3.8 billion. The deal is expected to close in the third quarter of 2026.
Analysts Take Opposite Corners
H.C. Wainwright and Jefferies both downgraded Atai Beckley in the wake of the announcement. Wainwright moved from Buy to Neutral, slashing its price target from $25 to $7.50, while Jefferies shifted from Buy to Hold, also landing at $7.50. Both firms argued that with the takeover effectively priced in, there is little room for the stock to move beyond the deal’s terms.
Oppenheimer, however, stands apart. The firm maintained its Outperform rating and a $16 price target — more than double the maximum possible payout from the cash-and-CVR structure. That gap suggests Oppenheimer either sees lingering uncertainty around the deal’s completion or believes the pipeline holds value that the current transaction structure fails to capture.
Should investors sell immediately? Or is it worth buying Atai Beckley?
The Milestone Mechanics
The CVR component is far from a guaranteed payout. One dollar per share becomes payable if VLS-01, a buccal DMT candidate currently in Phase 2b, enters Phase 3. Another $0.50 is triggered upon approval or rescheduling of BPL-003, the lead asset. A final dollar is tied to approval or rescheduling of VLS-01. The structure means a meaningful portion of the deal’s value hinges on actual clinical and regulatory progress, not just the upfront cash.
BPL-003, an intranasal 5-MeO-DMT treatment for treatment-resistant depression, is already in Phase 3 and holds FDA Breakthrough Therapy designation. Phase 2b data showed rapid and sustained symptom relief. The pipeline also includes EMP-01, an MDMA-based candidate for social anxiety disorder. Together, the assets cover multiple high-potential indications in the psychedelic medicine space.
Regulatory Tailwinds and Political Scrutiny
The acquisition arrives at a moment when psychedelic therapies are gaining institutional traction in the U.S. On July 13, 2026, the Department of Health and Human Services and the Department of Veterans Affairs agreed to a five-year collaboration to advance research into psychedelic substances, particularly for veteran care. The same day, the FDA released final guidance on psychedelic drug development. That dual regulatory push likely factored into Lilly’s decision to move now.
Yet the buyer itself faces heightened scrutiny. A House committee is examining Lilly’s clinical trials in China, adding a layer of political attention to the company’s already aggressive acquisition pace — this marks Lilly’s eleventh drugmaker purchase this year alone.
Market Reaction: Priced In, but Not Fully
Atai Beckley shares closed recently at €6.30, up 0.80% on the day, and have surged 77.97% over the past 30 days — a clear reflection of the deal’s announcement. The stock hit a 52-week high of €7.85 on July 16, the day the deal was disclosed, but remains about 19.75% below that peak. That gap suggests the market is pricing in some uncertainty around the closing timeline and the CVR payouts.
Atai Beckley at a turning point? This analysis reveals what investors need to know now.
The secondary article pegs the stock at €6.35 with a 1.60% daily gain and a 79.38% 30-day rally, with the Relative Strength Index at 75.7, signaling overbought conditions. The slight discrepancy between the two data points likely reflects intraday movement, but the overall picture is consistent: the market has largely absorbed the cash component while leaving room for CVR speculation.
Sector Ripple Effects
The Lilly deal has lifted the broader psychedelics space, though not uniformly. Compass Pathways, despite an upgrade from Evercore ISI — which raised its price target from $8 to $21 — fell 5.7% to a five-day low. Consolidation is also underway elsewhere: AbbVie acquired Gilgamesh for up to $1.2 billion, and Otsuka secured Transcend for a similar sum. The FDA guidance and the HHS-VA collaboration are providing additional sector-wide support.
For Atai Beckley investors, the near-term focus will be on the Phase 3 progress of BPL-003 and any regulatory signals that could accelerate or delay the deal’s third-quarter close. With the CVR structure tying a significant portion of the payout to actual milestones, the stock may continue to trade with a premium that reflects hope — and risk — beyond the cash bid.
Ad
Atai Beckley Stock: New Analysis - 22 July
Fresh Atai Beckley information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
